RLMD — Relmada Therapeutics, Inc.

Is RLMD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Relmada Therapeutics, Inc. (RLMD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.61. The rating moved from Overbought to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Relmada Therapeutics is a small, clinical‑stage biotech with upside tied to discrete clinical and corporate catalysts and downside tied to financing and clinical risk. Limited public financial disclosure and absent social/research coverage increase uncertainty, while sector trends toward outpatient behavioral‑health solutions provide a thematic tailwind. Near‑term performance will likely be driven by any upcoming readouts, partnership activity, or financing announcements; absent positive catalysts, expect continued volatility and sensitivity to market flows.

Key factors

  • Clinical-stage pipeline with potential readouts that could drive binary upside or downside
  • Limited publicly available recent financial/EDGAR data increases uncertainty around cash runway and dilution risk
  • Sector thematic tailwinds for at‑home/outpatient behavioral-health modalities could offer readthroughs if programs align
  • Small‑cap/biotech sensitivity to broader risk‑on/risk‑off swings; current market tone is cautiously optimistic but favors larger, more stable pharma names
  • Potential partnership or licensing opportunities could materially de‑risk or fund programs

Risks

  • Binary clinical trial outcomes that can cause sharp share price moves
  • Funding needs and the likelihood of dilutive financings or convertible deals
  • Low liquidity and high volatility common to microcap biotech names
  • Competitive pressure from larger pharmaceutical companies and alternative therapeutic modalities
  • Regulatory setbacks, slower-than-expected enrollment, or unfavorable safety/efficacy data

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RLMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.